Full text copy of the unanimous U.S. Supreme Court ruling in Association for Molecular Pathology v. Myriad Genetics that human genes may not be patented because they occur naturally in nature.
From Greg Stohr writing for Bloomberg:
“The U.S. Supreme Court restricted the ability of companies to patent human genetic sequences, ruling in a case that tested a decades-old practice and raised questions about thousands of biotechnology, agricultural and drug patents.
The justices unanimously issued a mixed ruling on Myriad Genetics Inc.’s patents on genes linked to breast and ovarian cancer. The majority said that some parts of Myriad’s patents improperly covered natural phenomena, while other parts require enough human intervention to be eligible for legal protection.
The ruling marks an important moment for patent law, with implications for the growing field of personalized medicine and efforts to map the human brain and discover new uses for embryonic stem cells.
The decision is a partial victory for doctors’ groups and patient advocates that accused Myriad of using its patents to block clinical testing and research. Biotechnology, agriculture and drug industries backed Myriad in the case, telling the court that gene patents have led to valuable treatments.”
Please see full publication below for more information.
